Vaccines Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration and Key Geographical Region

The vaccines market is estimated to grow from USD 48 billion in the current year to USD 94 billion by 2030, at a CAGR of 11.9% during the forecast period, till 2030.

Vaccines Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Vaccine API

Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Recombinant Vaccines
Toxoid Vaccines
Others

Targeted Patient Population

Pediatric
Adult

Type of Vaccines

Pneumococcal Conjugate Vaccine
Human Papillomavirus Vaccine
Influenza Vaccine
Rotavirus Vaccine
Varicella Vaccine
DTP-HepB-Hib Vaccine
Others

Route of Administration

Intramuscular
Subcutaneous
Oral Administration
Intravenous
Others

Key Geographical Region

North America
Europe
Rest of the World

VACCINES MARKET: GROWTH AND TRENDS

With the increasing threat of infectious diseases, there has been a rise in the need for vaccines worldwide. A vaccine is a type of biological formulation created using weakened or inactive microbes, along with their surface proteins and toxins. These vaccines offer active acquired immunity against specific diseases and allow the immune system to produce a robust response if a person encounters the same pathogen in the future. Vaccination is now a critical means of lowering the risk of infectious diseases and decreasing global mortality rates. The global emergence of infectious diseases has highlighted the need for improved vaccines to mitigate disease risks. Recently, the World Health Organization published a report on disease outbreaks, revealing the rising number of people affected by Avian influenza A and Mpox.

Moreover, the European Centre for Disease Prevention and Control reported that approximately 4.5 million dengue cases had been documented worldwide, with about 4,000 fatalities confirmed. In addition, the World Health Organization announced approximately 64 new infectious diseases impacting individuals worldwide. Further, approximately 2 million individuals affected by rotavirus are admitted to the hospital annually. In this context, numerous industry leaders, governmental bodies, and public health organizations have launched diverse immunization initiatives and concentrated on creating advanced vaccines. In was also recently reported that Biovac and Sanfoi established a collaboration for the manufacturing of inactivated polio vaccines in Africa. The aim of the collaboration is to increase the production of polio vaccines to satisfy the rising need for these vaccines in more than 40 African nations.

Additionally, French President Emmanuel Macron opted to collaborate with several African leaders in organizing a USD 1.1 billion initiative aimed at speeding up vaccine production in African nations. At present, various research projects have been launched by stakeholders to promote innovation in the healthcare sector and reduce the risk of transmitting infectious diseases. Due to the continuous need for vaccines and rising collaborations, the vaccine market is expected to expand at a consistent pace during the forecast period.

VACCINES MARKET: KEY INSIGHTS

The report delves into the current state of the vaccines market and identifies potential growth opportunities within industry. Some key findings from the report include:

More than 200 preventive vaccines, developed by both industry and non-industry players, are being evaluated in clinical stages of development.

A variety of vaccine APIs, designed for administration via multiple routes of delivery, are presently being investigated; most such candidates are in the early stages of development.
In order to achieve a competitive edge, vaccine developers are putting in significant efforts to ensure that their candidates are clinically and commercially competent.
Foreseeing a lucrative future in this domain, several private and public investors have invested over USD 10 billion in vaccine development initiatives, across 175 instances, in the time period since 2015.

Over the last few years, 1,400+ clinical trials evaluating various types of preventive vaccines have been registered, indicating the rapid pace of development in this field.
Around 70 companies, situated in different regions across the globe, claim to provide contract development, fill / finish and regulatory support, in addition to manufacturing services.

The market is anticipated to grow at a CAGR of 11.9%, till 2030, and the projected opportunity is likely to be distributed across various routes of administration, vaccine types and key geographical regions.

VACCINES MARKET: KEY SEGMENTS

Live Attenuated Vaccines Segment is Likely to Capture the Majority of the Market Share

In terms of the type of technology, the global market for vaccines is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, and others. Fueled by the rising need for potent vaccines to combat various infectious diseases, live attenuated vaccines are projected to occupy the largest segment, securing 28% of the total vaccines market share in the current year. Other types of vaccines will grow at a higher CAGR of 16.8% during the forecast period owing to the growing research on novel vaccines such as DNA vaccines.

Pediatric Segment Holds the Highest Vaccines Market Share

In terms of target patient population, the global market has been distributed into pediatrics and adults. According to our market study, the pediatric segment accounts for the largest share (56%) of the vaccines market in the current year. The expansion of the pediatric market segment is due to the rising emphasis on immunizing infants against illnesses and the increasing government efforts to promote vaccination among children. In the long run, the adult segment will grow at a higher CAGR of 12.1% during the forecast period, driven by the increasing cases of endemic and pandemics.

The Current Market Share is Captured by Intramuscular Segment

In terms of route of administration, the vaccines market is segmented into intramuscular, subcutaneous, oral, intravenous and others. According to our projection, the intramuscular segment capture majority (52%) of the overall vaccine market in the current year. The increase can be attributed to the rising preference for parenteral vaccines, as they can avoid the gastrointestinal tract. The intramuscular route facilitates easy administration and produces fewer side effects. In the long term, the intravenous segment is expected to grow at a higher CAGR of 14.6% throughout the forecast period.

MMR Vaccines will Grow at a Higher CAGR of 12.3% during the Forecast Period

In terms of the type of vaccines, the market is segmented into Pneumococcal Conjugate Vaccine, Human Papillomavirus Vaccine, Rotavirus Vaccine, Influenza Vaccine, MMR Vaccine, Tetanus and Diphtheria Booster Vaccine, Varicella Vaccine, DTaP-Hib-IPV Vaccine, DTaP-HepB-Hib-IPV Vaccine and other. Driven by the growing incidences of infectious diseases, the others segment accounts to hold the largest (32.4%) vaccines market share in the current year. Additionally, the pneumococcal conjugate vaccine accounts to hold the second highest share 25.8% of the market currently. Pfizer with its Prevnar series and Merck are the market leaders in pneumococcal vaccine market. Merck received US FDA approval for its 21-valent pneumococcal vaccine, CAPVAXIVE recently. In the long run, MMR vaccines will grow at a higher CAGR of 12.3% during the forecast period.

North America Accounts for the Highest Revenues in the Global Vaccines Market in the Current Year

In terms of key geographies, the global market has been distributed across North America, Europe, Asia-Pacific and Rest of the World. According to our projections, North America accounts for the largest share (44%) of the market in the current year. The primary factors driving the growth of the vaccine market in this area are the heightened focus on vaccination implementation, the fast-expanding healthcare industry, and a rise in vaccine research in the US. However, the demand for vaccines in Asia-Pacific is estimated to witness growth and is likely to grow at a substantial CAGR of 14.7% during the forecast period. In February 2023, the Government of India forged a new three-year partnership with Gavi (Leading Vaccine Alliance) with the aim of immunizing millions of children in India with appropriate vaccines. Under this agreement, Gavi has allocated USD 250 million for the identification and vaccination of children who haven’t received any vaccine strengthening healthcare systems and supporting the introduction of HPV (human papillomavirus vaccine) along with TCV (typhoid conjugate vaccine) into India’s national routine immunization schedule.

Market Share by Key Players

The key players active in this industry are Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur and Valneva. Currently, GlaxoSmithKline accounts to hold 21% of the overall vaccines market share in the current year. The highest share can be attributed to its extensive range of vaccines and GlaxoSmithKline's acceleration of research and development efforts in the vaccine sector.

Example Players in Vaccines Market

Bio Farma
Emergent BioSolutions
GC Pharma
GlaxoSmithKline
Janssen
Merck
Novavax
Moderna
Pfizer
Sanofi Pasteur
Valneva

VACCINES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the vaccines market, focusing on key market segments, including [A] type of vaccine API, [B] targeted patient population, [C] type of vaccines, [D] route of administration, and [E] key geographical regions.
Market Landscape: A detailed assessment of the current market landscape of over 200 preventive vaccines that are currently being evaluated in different stages of development, based on a number of parameters, such as [A] type of developer, [B] phase of development of lead candidates, [C] route of administration, [D] type of vaccine API, [E] dosage form, dosage, [F] target disease indication and [G] target patient population.
Company Competitiveness Analysis: A comprehensive competitive analysis of of preventive vaccine developers based in North America, Europe and Asia-Pacific, examining factors, such as [A] supplier strength and [B] pipeline strength.
Company Profiles: In-depth profiles of the key preventive vaccine developers based in North America, Europe and Asia-Pacific that are engaged in manufacturing focusing on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
Clinical Trial Analysis: A detailed analysis of various completed, ongoing and planned clinical studies of preventive vaccines based on various relevant parameters, including [A] trial registration year, [B] phase of development, [C] trial recruitment status, [D] study design, [E] trial focus area, [F] type of preventive vaccine, [G] target disease indication(s), [H] type of sponsor / collaborator, [I] leading industry sponsors / collaborators, [J] enrolled patients population and [K] regional distribution.
Ongoing Vaccine Development Initiatives for Complex Conditions: An overview of the ongoing vaccine development initiatives for complex conditions, such as [A] COVID-19, [B] Ebola virus disease, [C] HIV / AIDS, [D] malaria and [E] zika virus infection, including information on disease, its global burden, current treatment landscape and preventive vaccine research landscape.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What is the current global capacity of developers?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs Covering All Analytical Modules
Up to 15% Complimentary Content Customization
In-Depth Report Walkthrough with the Research Team
Complimentary Report Update if the Report is 6+ Months Old

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Preventive Vaccines
3.2.1. Classification of Vaccines
3.2.1.1. Live, Attenuated Vaccines
3.2.1.2. Inactivated Vaccines
3.2.1.3. Subunit Vaccines
3.2.1.4. Toxoid Vaccines
3.2.1.5. DNA Vaccines
3.2.2. Key Components of a Vaccine Formulation
3.2.3. Production of Vaccines using Different Expression Systems
3.2.3.1. Embryonated Chicken Eggs and Primary Chicken Embryonic Fibroblasts (CEFs)
3.2.3.2. Mammalian Expression Systems
3.2.3.3. Avian Expression Systems
3.2.3.4. Plant Expression Systems
3.2.3.5. Bacterial Expression Systems
3.2.3.6. Yeast Expression Systems
3.2.3.7. Insect Expression System
3.2.4. Routes of Vaccine Administration
3.2.4.1. Intramuscular Route
3.2.4.2. Subcutaneous Route
3.2.4.3. Oral Route
3.2.4.4. Intranasal Route
3.2.4.5. Intradermal Route
3.2.4.6. Inhalation
3.2.5. Clinical Development and Approval of Vaccines
3.2.6. Future Perspectives

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Preventive Vaccines: Overall Market Landscape
4.2.1. Marketed Vaccines Landscape
4.2.2. Clinical-Stage Vaccines Landscape
4.2.2.1. Analysis by Type of Developer
4.2.2.2. Analysis by Phase of Development
4.2.2.3. Analysis by Route of Administration
4.2.2.4. Analysis by Type of Vaccine API
4.2.2.5. Analysis by Dosage Form
4.2.2.6. Analysis by Dosage
4.2.2.7. Analysis by Target Disease Indication
4.2.2.8. Analysis by Target Patient Population
4.2.2.9. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
4.2.2.10. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development

5. COMPANY COMPETITIVENESS ANALYSIS

5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Preventive Vaccine Developers
5.4.1. Preventive Vaccine Developers based in North America
5.4.2. Preventive Vaccine Developers based in Europe
5.4.3. Preventive Vaccine Developers based in Asia Pacific

6. COMPANY PROFILES

6.1. Chapter Overview
6.2. Bio Farma
6.2.1. Company Overview
6.2.2. Preventive Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Emergent BioSolutions
6.3.1. Company Overview
6.3.2. Preventive Vaccines Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. GC Pharma
6.4.1. Company Overview
6.4.2. Preventive Vaccines Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. GlaxoSmithKline
6.5.1. Company Overview
6.5.2. Preventive Vaccines Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Janssen
6.6.1. Company Overview
6.6.2. Preventive Vaccines Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Merck
6.7.1. Company Overview
6.7.2. Preventive Vaccines Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Novavax
6.8.1. Company Overview
6.8.2. Preventive Vaccines Portfolio
6.8.3. Recent Developments and Future Outlook
6.9. Pfizer
6.9.1. Company Overview
6.9.2. Preventive Vaccines Portfolio
6.9.3. Recent Developments and Future Outlook
6.10. Sanofi Pasteur
6.10.1. Company Overview
6.10.2. Preventive Vaccines Portfolio
6.10.3. Recent Developments and Future Outlook
6.11. Valneva
6.11.1. Company Overview
6.11.2. Preventive Vaccines Portfolio
6.11.3. Recent Developments and Future Outlook

7. CLINICAL TRIAL ANALYSIS

7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Preventive Vaccines: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Enrolled Patient Population and Trial Registration Year
7.3.3. Analysis by Trial Phase
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Study Design
7.3.6. Analysis by Trial Focus Area
7.3.7. Analysis by Type of Preventive Vaccine (based on Pathogen)
7.3.8. Analysis by Target Disease Indication
7.3.9. Analysis by Type of Sponsor / Collaborator
7.3.10. Leading Industry Players: Analysis by Number of Registered Trials
7.3.11. Geographical Analysis by Number of Registered Trials
7.3.12. Geographical Analysis by Enrolled Patient Population
7.3.13. Geographical Analysis by Trial Recruitment Status

8. ONGOING VACCINE DEVELOPMENT INITIATIVES FOR COMPLEX CONDITIONS

8.1. Chapter Overview
8.2. Coronavirus Disease (COVID-19)
8.2.1. Disease Overview
8.2.2. Global Burden of COVID-19
8.2.3. Current Treatment Landscape
8.2.4. Preventive Vaccines for COVID-19
8.2.4.1. Historical Background of COVID-19 Vaccine Research
8.2.4.2. COVID-19 and Affiliated Research Landscape
8.2.5. Funding Instances
8.2.6. Recent Developments
8.3. Ebola Virus Disease (EVD)
8.3.1. Disease Overview
8.3.2. Global Burden of EVD
8.3.3. Current Treatment Landscape
8.3.4. Preventive Vaccines for EVD
8.3.4.1. Historical Background of Ebola Virus Vaccine Research
8.3.4.2. Anti-Ebola Virus Vaccines and Affiliated Research Landscape
8.3.5. Funding Instances
8.3.6. Recent Developments
8.4. HIV/AIDS
8.4.1. Disease Overview
8.4.2. Global Burden of HIV/AIDS
8.4.3. Current Treatment Landscape
8.4.4. Preventive Vaccines for HIV/AIDS
8.4.4.1. Historical Background of HIV/AIDS Vaccine Research
8.4.4.2. Anti-HIV Vaccines and Affiliated Research Landscape
8.4.5. Funding Instances
8.4.6. Recent Developments
8.5. Malaria
8.5.1. Disease Overview
8.5.2. Global Burden of Malaria
8.5.3. Current Treatment Landscape
8.5.4. Preventive Vaccines for Malaria
8.5.4.1. Historical Background of Malaria Vaccine Research
8.5.4.2. Anti-Malaria Vaccines and Affiliated Research Landscape
8.5.5. Funding Instances
8.5.6. Recent Developments
8.6. Zika Virus Infection
8.6.1. Disease Overview
8.6.2. Global Burden of Zika Virus Infection
8.6.3. Current Treatment Landscape
8.6.4. Preventive Vaccines for Zika Virus Infection
8.6.4.1. Historical Background of Zika Virus Vaccine Research
8.6.4.2. Anti-Zika Virus Vaccines and Affiliated Research Landscape
8.6.5. Funding Instances
8.6.6. Recent Developments

9. FUNDING AND INVESTMENT ANALYSIS

9.1. Chapter Overview
9.2. Types of Funding
9.3. Preventive Vaccines: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Amount Invested across Different Types of Vaccine API
9.3.5. Analysis by Focus Area
9.3.6. Analysis by Amount Invested by Different Type of Investors
9.3.7. Most Active Players: Analysis by Number of Funding Instances
9.3.8. Most Active Investors: Analysis by Number of Funding Instances
9.3.9. Analysis by Geography
9.3.9.1. Continent-wise Analysis
9.3.9.2. Country-wise Analysis

10. MARKET SIZING AND OPPORTUNITY ANALYSIS

10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Overall Preventive Vaccines Market, till 2030
10.3.1. Preventive Vaccines Market, till 2030: Distribution by Route of Administration
10.3.2. Preventive Vaccines Market, till 2030: Distribution by Type of Vaccine
10.3.3. Preventive Vaccines Market, till 2030: Distribution by Type of Vaccine API
10.3.4. Preventive Vaccines Market, till 2030: Distribution by Target Patient Population
10.3.5. Preventive Vaccines Market, till 2030: Distribution by Key Geographical Regions
10.3.5.1. Preventive Vaccines Market in North America, till 2030
10.3.5.1.1. Preventive Vaccines Market in the US, till 2030
10.3.5.1.2. Preventive Vaccines Market in Mexico, till 2030
10.3.5.1.3. Preventive Vaccines Market in Canada, till 2030
10.3.5.2. Preventive Vaccines Market in Europe, till 2030
10.3.5.2.1. Preventive Vaccines Market in Spain, till 2030
10.3.5.2.2. Preventive Vaccines Market in the UK, till 2030
10.3.5.2.3. Preventive Vaccines Market in Italy, till 2030
10.3.5.2.4. Preventive Vaccines Market in France, till 2030
10.3.5.2.5. Preventive Vaccines Market in Germany, till 2030
10.3.5.2.6. Preventive Vaccines Market in Rest of Europe, till 2030
10.3.5.3. Preventive Vaccines Market in Asia Pacific, till 2030
10.3.5.3.1. Preventive Vaccines Market in India, till 2030
10.3.5.3.2. Preventive Vaccines Market in China, till 2030
10.3.5.3.3. Preventive Vaccines Market in Australia, till 2030
10.3.5.3.4. Preventive Vaccines Market in Rest of Asia Pacific, till 2030
10.3.5.4. Preventive Vaccines Market in Rest of the World, till 2030

11. CASE-IN-POINT: CONTRACT MANUFACTURING OF VACCINES

11.1. Chapter Overview
11.2. Vaccine Contract Manufacturing
11.2.1. Addressing an Unmet Need
11.2.2. Commonly Outsourced Operations
11.2.3. Selecting a CMO Partner
11.2.4. Advantages of Outsourcing Manufacturing Services
11.2.5. Associated Risks and Challenges
11.3. Vaccine Contract Manufacturing: Overall Market Landscape
11.3.1. Analysis by Year of Establishment
11.3.2. Analysis by Company Size
11.3.3. Analysis by Scale of Operation
11.3.4. Analysis by Location of Headquarters
11.3.5. Analysis by Location of Manufacturing Facilities
11.3.6. Analysis by Type of Service(s) Offered
11.3.7. Analysis by Expression System Used
11.3.8. Analysis by Type of Vaccine Manufactured
11.3.9. Analysis by Type of Vaccine Manufactured and Location of Headquarters

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

13.1. Chapter Overview
13.2. Company A
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Chief Executive Officer

14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Research Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 4.1 Executive Summary: Pre-Sterilized / Ready to Use Containers Market Landscape
Figure 4.2 Executive Summary: Pre-Sterilized / Ready to Use Closures Market Landscape
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Market Entry Decision Making Framework
Figure 4.5 Executive Summary: Demand Analysis
Figure 4.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Advantages of Pharmaceutical Packaging
Figure 5.2 Type of Pharmaceutical Packaging
Figure 5.3 Innovation in Pharmaceutical Packaging and Value Chain
Figure 5.4 Ready to Use Enables Flexible, Flexible Aseptic Processing
Figure 5.5 Advantages of Ready to Use Platform
Figure 5.6 Drivers of Ready to Use Platform
Figure 6.1 Pre-Sterilized / Ready to Use Containers: Distribution by Type of Container
Figure 6.2 Pre-Sterilized / Ready to Use Containers: Distribution by Material(s) of Fabrication
Figure 6.3 Pre-Sterilized / Ready to Use Containers: Distribution by Container Color
Figure 6.4 Pre-Sterilized / Ready to Use Containers: Distribution by Type of Compatible Drug(s)
Figure 6.5 Pre-Sterilized / Ready to Use Containers: Distribution by Scale of Operation
Figure 6.6 Pre-Sterilized / Ready to Use Containers: Distribution by Packaging Format(s)
Figure 6.7 Pre-Sterilized / Ready to Use Containers: Distribution by Sterilization Technique(s) Used
Figure 6.8 Pre-Sterilized / Ready to Use Containers: Distribution by Quality Certification(s) Obtained
Figure 6.9 Pre-Sterilized / Ready to Use Containers: Distribution by Target Market
Figure 6.10 Pre-Sterilized / Ready to Use Containers: Distribution by Availability of Additional Coating
Figure 6.11 Pre-Sterilized / Ready to Use Containers: Distribution by Availability of RTU Kits
Figure 6.12 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Year of Establishment
Figure 6.13 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Company Size
Figure 6.14 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 6.15 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 6.16 Leading Manufacturers: Distribution by Number of Products
Figure 7.1 Pre-Sterilized / Ready to Use Closures: Distribution by Type of Closure
Figure 7.2 Pre-Sterilized / Ready to Use Closures: Distribution by Material(s) of Fabrication
Figure 7.3 Pre-Sterilized / Ready to Use Closures: Distribution by Type of Compatible Container(s)
Figure 7.4 Pre-Sterilized / Ready to Use Closures: Distribution by Type of Compatible Drug(s)
Figure 7.5 Pre-Sterilized / Ready to Use Closures: Distribution by Sterilization Technique(s) Used
Figure 7.6 Pre-Sterilized / Ready to Use Closures: Distribution by Available Finish Format(s)
Figure 7.7 Pre-Sterilized / Ready to Use Closures: Distribution by Quality Certification(s) Obtained
Figure 7.8 Pre-Sterilized / Ready to Use Closures: Distribution by Target Market
Figure 7.9 Pre-Sterilized / Ready to Use Closures: Distribution by Availability of Additional Coating
Figure 7.10 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Year of Establishment
Figure 7.11 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Company Size
Figure 7.12 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 7.13 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 7.14 Leading Manufacturers: Distribution by Number of Products
Figure 8.1 Key Insights: Distribution by Type of Container and Scale of Operation
Figure 8.2 Key Insights: Distribution by Type of Container and Packaging Format(s)
Figure 8.3 Key Insights: Distribution by Type of Container and Material(s) of Fabrication
Figure 8.4 Key Insights: Distribution by Type of Container and Container Color
Figure 8.5 Key Insights: Distribution by Type of Container and Sterilization Technique(s) Used
Figure 8.6 Key Insights: Distribution by Type of Container and Type of Compatible Drug(s)
Figure 8.7 Key Insights: Distribution by Material(s) of Fabrication and Sterilization Technique(s) Used
Figure 8.8 Key Insights: Distribution by Type of Closure and Material(s) of Fabrication
Figure 8.9 Key Insights: Distribution by Type of Closure and Sterilization Technique(s) Used
Figure 8.10 Key Insights: Distribution by Type of Closure and Available Finish Format(s)
Figure 8.11 Key Insights: Distribution by Type of Closure and Type of Compatible Drug(s)
Figure 9.1 Product Competitiveness Analysis: Vials
Figure 9.2 Product Competitiveness Analysis: Syringes
Figure 9.3 Product Competitiveness Analysis: Bags
Figure 9.4 Product Competitiveness Analysis: Cartridges
Figure 10.1 Product Competitiveness Analysis: Stoppers
Figure 10.2 Product Competitiveness Analysis: Plungers
Figure 10.3 Product Competitiveness Analysis: Caps
Figure 10.4 Product Competitiveness Analysis: Tip Caps / Needle Shields
Figure 10.5 Product Competitiveness Analysis: Seals
Figure 11.1 Aptar: Annual Revenues, Since 2016 (USD Billion)
Figure 11.2 Datwyler: Annual Revenues, Since 2016 (CHF Billion)
Figure 11.3 SCHOTT: Annual Revenues, Since 2016 (EUR Billion)
Figure 11.4 West Pharmaceutical Services: Annual Revenues, Since 2018 (USD Billion)
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 12.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2015
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 12.7 Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 12.8 Partnerships and Collaborations: Distribution by Type of Packaging System
Figure 12.9 Partnerships and Collaborations: Distribution by Type of Packaging Material
Figure 12.10 Most Active Players: Distribution by Number of Partnerships
Figure 12.11 Partnerships and Collaborations: Local and International Agreements
Figure 12.12 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 13.1 Spider Web Analysis: Product Reach
Figure 13.2 Spider Web Analysis: Product Differentiation
Figure 13.3 Spider Web Analysis: Market Activity
Figure 13.4 Spider Web Analysis: Product Competitiveness
Figure 13.5 Spider Web Analysis: Manufacturing Complexity
Figure 13.6 Market Entry Decision Making Framework: Concluding Remarks
Figure 14.1 Demand for Pre-Sterilized / Ready to Use Vials, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.2 Demand for Pre-Sterilized / Ready to Use Syringes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.3 Demand for Pre-Sterilized / Ready to Use Cartridges, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.4 Demand for Pre-Sterilized / Ready to Use Caps, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.5 Demand for Pre-Sterilized / Ready to Use Plungers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.6 Demand for Pre-Sterilized / Ready to Use Seals, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.7 Demand for Pre-Sterilized / Ready to Use Stoppers, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.8 Demand for Pre-Sterilized / Ready to Use Tip Caps / Needle Shields, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.9 Demand for Pre-Sterilized / Ready to Use Aluminum Containers and Closures, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.10 Demand for Pre-Sterilized / Ready to Use Glass Containers and Closures, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.11 Demand for Pre-Sterilized / Ready to Use Plastic Containers and Closures, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.12 Demand for Pre-Sterilized / Ready to Use Rubber Containers and Closures, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.13 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.14 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.15 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Asia, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.16 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.17 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 14.18 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Rest of the World, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 16.1 Percentage Distribution of Production and Processing Costs for Primary Packaging Components
Figure 16.2 Global Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 16.3 Global Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market: Conservative Scenario
Figure 16.4 Global Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market: Optimistic Scenario
Figure 16.5 Dynamic Dashboard
Figure 17.1 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market: Distribution by Type of Container (USD Billion)
Figure 17.2 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Vials: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.3 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Syringes: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 17.4 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Cartridges: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.1 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market: Distribution by Type of Closure (USD Billion)
Figure 18.2 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Caps: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.3 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Plungers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.4 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Seals: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.5 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Stoppers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 18.6 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Tip Caps / Needle Shields: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.1 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Aluminum Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 19.2 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Glass Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 19.3 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Plastic Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 19.4 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Rubber Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.1 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.2 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.3 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.4 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.5 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.6 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.7 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Asia: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.8 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Asia: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.9 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Asia: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.10 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.11 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.12 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.13 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.14 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.15 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.6 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Rest of the World: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.17 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Rest of the World: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 20.18 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Rest of the World: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Figure 21.1 Emerging Trends in Pharmaceutical Packaging
Figure 21.2 Future Growth Opportunities for Ready to Use Containers and Closures Based on Recent Trends
Figure 22.1 Key Considerations for Selecting a Robotic System
Figure 22.2 Pharmaceutical Manufacturing: Advantages of Robotic Systems
Figure 22.3 Pharmaceutical Manufacturing: Disadvantages of Robotic Systems
Figure 23.1 Concluding Remarks: Pre-Sterilized / Ready to Use Containers Market Landscape
Figure 23.2 Concluding Remarks: Pre-Sterilized / Ready to Use Closures Market Landscape
Figure 23.3 Concluding Remarks: Partnerships and Collaborations
Figure 23.4 Concluding Remarks: Market Entry Decision Making Framework
Figure 23.5 Concluding Remarks: Demand Analysis
Figure 23.6 Concluding Remarks: Market Forecast

LIST OF TABLES

Table 5.1 Compatibility of Polymers with Ethylene Oxide Sterilization
Table 5.2 Advantages and Disadvantages of Different Sterilization Techniques
Table 6.1 Pre-Sterilized / Ready to Use Containers: Information on Type of Container, Material(s) of Fabrication, Container Color and Type of Compatible Drug(s)
Table 6.2 Pre-Sterilized / Ready to Use Containers: Information on Scale of Operation, Packaging Format(s) and Sterilization Technique(s) Used
Table 6.3 Pre-Sterilized / Ready to Use Containers: Information on Quality Certification(s) Obtained and Target Market
Table 6.4 Pre-Sterilized / Ready to Use Containers: Information on Availability of Additional Coating and RTU Kits
Table 6.5 Pre-Sterilized / Ready to Use Containers: List of Manufacturers
Table 7.1 Pre-Sterilized / Ready to Use Closures: Information on Type of Closure, Material(s) of Fabrication, Type of Compatible Container(s), Type of Compatible Drug(s) and Sterilization Technique(s) Used
Table 7.2 Pre-Sterilized / Ready to Use Closures: Information on Available Finish Format(s), Quality Certification(s) Obtained and Target Market
Table 7.3 Pre-Sterilized / Ready to Use Closures: Information on Availability of Additional Coating
Table 7.4 Pre-Sterilized / Ready to Use Closures: List of Manufacturers
Table 11.1 Leading Ready to Use Container and Closure Manufacturers
Table 11.2 APG Pharma Packaging: Company Snapshot
Table 11.3 APG Pharma Packaging: Ready to Use Closures
Table 11.4 Aptar: Company Snapshot
Table 11.5 Aptar: Ready to Use Closures
Table 11.6 Aptar: Recent Developments and Future Outlook
Table 11.7 Daikyo Seiko: Company Snapshot
Table 11.8 Daikyo Seiko: Ready to Use Containers
Table 11.9 Daikyo Seiko: Ready to Use Closures
Table 11.10 Datwyler: Company Snapshot
Table 11.11 Datwyler: Ready to Use Closures
Table 11.12 Datwyler: Recent Developments and Future Outlook
Table 11.13 DWK Life Sciences: Company Snapshot
Table 11.14 DWK Life Sciences: Ready to Use Containers
Table 11.15 DWK Life Sciences: Ready to Use Closures
Table 11.16 DWK Life Sciences: Recent Developments and Future Outlook
Table 11.17 Ningbo Zhengli Pharmaceutical Packaging: Company Snapshot
Table 11.18 Ningbo Zhengli Pharmaceutical Packaging: Ready to Use Containers
Table 11.19 Ningbo Zhengli Pharmaceutical Packaging: Recent Developments and Future Outlook
Table 11.20 SCHOTT: Company Snapshot
Table 11.21 SCHOTT: Ready to Use Containers
Table 11.22 SCHOTT: Ready to Use Closures
Table 11.23 SCHOTT: Recent Developments and Future Outlook
Table 11.24 Stevanato: Company Snapshot
Table 11.25 Stevanato: Ready to Use Containers
Table 11.26 Stevanato: Ready to Use Closures
Table 11.27 Stevanato: Recent Developments and Future Outlook
Table 11.28 West Pharmaceutical Services: Company Snapshot
Table 11.29 West Pharmaceutical Services: Ready to Use Containers
Table 11.30 West Pharmaceutical Services: Ready to Use Closures
Table 11.31 West Pharmaceutical Services: Recent Developments and Future Outlook
Table 12.1 Pre-Sterilized / Ready to Use Containers and Closures: List of Partnerships and Collaborations, Since 2015
Table 14.1 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging: Distribution by Type of Container
Table 14.2 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging: Distribution by Type of Closure
Table 14.3 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging: Distribution by Material of Fabrication
Table 14.4 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging: Distribution by Key Geographical Regions
Table 16.1 Tiered Pricing Structure for Pre-Sterilized / RTU Pharmaceutical Packaging across Different Geographies
Table 22.1 List of Pharmaceutical Robotics Manufacturers
Table 22.2 Aseptic Technologies: Company Overview
Table 22.3 Aseptic Technologies: Key Specifications of Crystal L1 Robot Line
Table 22.4 Aseptic Technologies: Key Specifications of Crystal SL1 Robot Line
Table 22.5 AST: Company Overview
Table 22.6 AST: Key Specifications of ASEPTiCell
Table 22.7 AST: Key Specifications of GENiSYS R
Table 22.8 AST: Key Specifications of GENiSYS C
Table 22.9 AST: Key Specifications of GENiSYS Lab
Table 22.10 Bosch Packaging Technology: Company Overview
Table 22.11 Bosch Packaging Technology: Key Specifications of ATO
Table 22.12 Dara Pharma: Company Overview
Table 22.13 Dara Pharma: Key Specifications of SYX-E Cartridge + RABS
Table 22.14 Fedegari: Company Overview
Table 22.15 Fedegari: Key Specifications of Fedegari Isolator
Table 22.16 IMA: Company Overview
Table 22.17 IMA: Key Specifications of INJECTA
Table 22.18 IMA: Key Specifications of STERI LIF3
Table 22.19 Steriline: Company Overview
Table 22.20 Steriline: Key Specifications of Robotic Nest Filling Machine
Table 22.21 Steriline: Key Specifications of Robotic Vial Filling Machine
Table 22.22 Steriline: Key Specifications of Robotic Vial Capping Machine)
Table 22.23 Vanrx Pharmasystems: Company Overview
Table 22.24 Vanrx Pharmasystems: Key Specifications of Microcell Vial Filler
Table 22.25 Key Specifications of SA25 Aseptic Filling Workcell
Table 24.1 Jinan Youlyy Industrial: Company Snapshot
Table 24.2 Sagar Rubber: Company Snapshot
Table 24.3 Aseptic Technologies: Company Snapshot
Table 24.4 BioPhorum Operations: Company Snapshot
Table 24.5 PYRAMID Laboratories: Company Snapshot
Table 25.1 Pre-Sterilized / Ready to Use Containers: Distribution by Type of Container
Table 25.2 Pre-Sterilized / Ready to Use Containers: Distribution by Material(s) of Fabrication
Table 25.3 Pre-Sterilized / Ready to Use Containers: Distribution by Container Color
Table 25.4 Pre-Sterilized / Ready to Use Containers: Distribution by Type of Compatible Drug(s)
Table 25.5 Pre-Sterilized / Ready to Use Containers: Distribution by Scale of Operation
Table 25.6 Pre-Sterilized / Ready to Use Containers: Distribution by Packaging Format(s)
Table 25.7 Pre-Sterilized / Ready to Use Containers: Distribution by Sterilization Technique(s) Used
Table 25.8 Pre-Sterilized / Ready to Use Containers: Distribution by Quality Certification(s) Obtained
Table 25.9 Pre-Sterilized / Ready to Use Containers: Distribution by Target Market
Table 25.10 Pre-Sterilized / Ready to Use Containers: Distribution by Availability of Additional Coating
Table 25.11 Pre-Sterilized / Ready to Use Containers: Distribution by Availability of RTU Kits
Table 25.12 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Year of Establishment
Table 25.13 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Company Size
Table 25.14 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 25.15 Pre-Sterilized / Ready to Use Container Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 25.16 Leading Manufacturers: Distribution by Number of Products
Table 25.17 Pre-Sterilized / Ready to Use Closures: Distribution by Type of Closure
Table 25.18 Pre-Sterilized / Ready to Use Closures: Distribution by Material(s) of Fabrication
Table 25.19 Pre-Sterilized / Ready to Use Closures: Distribution by Type of Compatible Container(s)
Table 25.20 Pre-Sterilized / Ready to Use Closures: Distribution by Type of Compatible Drug(s)
Table 25.21 Pre-Sterilized / Ready to Use Closures: Distribution by Sterilization Technique(s) Used
Table 25.22 Pre-Sterilized / Ready to Use Closures: Distribution by Available Finish Format(s)
Table 25.23 Pre-Sterilized / Ready to Use Closures: Distribution by Quality Certification(s) Obtained
Table 25.24 Pre-Sterilized / Ready to Use Closures: Distribution by Target Market
Table 25.25 Pre-Sterilized / Ready to Use Closures: Distribution by Availability of Additional Coating
Table 25.26 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Year of Establishment
Table 25.27 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Company Size
Table 25.28 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 25.29 Pre-Sterilized / Ready to Use Closure Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 25.30 Leading Manufacturers: Distribution by Number of Products
Table 25.31 Key Insights: Distribution by Type of Container and Scale of Operation
Table 25.32 Key Insights: Distribution by Type of Container and Packaging Format(s)
Table 25.33 Key Insights: Distribution by Type of Container and Material(s) of Fabrication
Table 25.34 Key Insights: Distribution by Type of Container and Container Color
Table 25.35 Key Insights: Distribution by Type of Container and Sterilization Technique(s) Used
Table 25.36 Key Insights: Distribution by Type of Container and Type of Compatible Drug(s)
Table 25.37 Key Insights: Distribution by Material(s) of Fabrication and Sterilization Technique(s) Used
Table 25.38 Key Insights: Distribution by Type of Closure and Material(s) of Fabrication
Table 25.39 Key Insights: Distribution by Type of Closure and Sterilization Technique(s) Used
Table 25.40 Key Insights: Distribution by Type of Closure and Available Finish Format(s)
Table 25.41 Key Insights: Distribution by Type of Closure and Type of Compatible Drug(s)
Table 25.42 Aptar: Annual Revenues, Since 2016 (USD Billion)
Table 25.43 Datwyler: Annual Revenues, Since 2016 (CHF Billion)
Table 25.44 SCHOTT: Annual Revenues, Since 2019 (EUR Billion)
Table 25.45 West Pharmaceutical Services: Annual Revenues, Since 2018 (USD Billion)
Table 25.46 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2015
Table 25.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.48 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 25.49 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner, Since 2015
Table 25.51 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 25.52 Partnerships and Collaborations: Distribution by Purpose(s) of Partnership
Table 25.53 Partnerships and Collaborations: Distribution by Type of Packaging System
Table 25.54 Partnerships and Collaborations: Distribution by Type of Packaging Material
Table 25.55 Most Active Players: Distribution by Number of Partnerships
Table 25.56 Partnerships and Collaborations: Local and International Agreements
Table 25.57 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 25.58 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging, Till 2035: Distribution by Type of Container
Table 25.59 Demand for Pre-Sterilized / Ready to Use Vials, Till 2035
Table 25.60 Demand for Pre-Sterilized / Ready to Use Syringes, Till 2035
Table 25.61 Demand for Pre-Sterilized / Ready to Use Cartridges, Till 2035
Table 25.62 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging, Till 2035: Distribution by Type of Closure
Table 25.63 Demand for Pre-Sterilized / Ready to Use Caps, Till 2035
Table 25.64 Demand for Pre-Sterilized / Ready to Use Plungers, Till 2035
Table 25.65 Demand for Pre-Sterilized / Ready to Use Seals, Till 2035
Table 25.66 Demand for Pre-Sterilized / Ready to Use Stoppers, Till 2035
Table 25.67 Demand for Pre-Sterilized / Ready to Use Tip Caps / Needle Shields, Till 2035
Table 25.68 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging, Till 2035: Distribution by Material of Fabrication
Table 25.69 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging for Aluminum Containers and Closures, Till 2035
Table 25.70 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging for Glass Containers and Closures, Till 2035
Table 25.71 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging for Plastic Containers and Closures, Till 2035
Table 25.72 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging for Rubber Containers and Closures, Till 2035
Table 25.73 Global Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging, Till 2035: Distribution by Geography
Table 25.74 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in North America, Till 2035
Table 25.75 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Europe, Till 2035
Table 25.76 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Asia, Till 2035
Table 25.77 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Latin America, Till 2035
Table 25.78 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Middle East and North Africa, Till 2035
Table 25.79 Demand for Pre-Sterilized / Ready to Use Pharmaceutical Packaging in Rest of the World, Till 2035
Table 25.80 Global Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.81 Global Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market, Till 2035: Optimistic Scenario
Table 25.82 Global Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market, Till 2035: Conservative Scenario
Table 25.83 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Vials: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.84 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Syringes: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.85 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Cartridges: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.86 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Caps: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.87 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Plungers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.88 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Seals: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.89 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Stoppers: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.90 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Tip Caps / Needle Shields: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.91 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Aluminum Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.92 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Glass Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.93 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Plastic Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.94 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Rubber Containers and Closures: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.95 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.96 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.97 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in North America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.98 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.99 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.100 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Europe: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.101 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Asia: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.102 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Asia: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.103 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Asia: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.104 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.105 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.106 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Latin America: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.107 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.108 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.109 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.110 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market in Rest of the World: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.111 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Containers in Rest of the World: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)
Table 25.112 Pre-Sterilized / Ready to Use Pharmaceutical Packaging Market for Closures in Rest of the World: Historical Trends (Since 2018) and Forecasted Estimates (Till 2035)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

3P Biopharmaceuticals
Abbott Biologicals
AbbVie Contract Manufacturing
Aberdeen Proving Ground
ABL
Abu Dhabi Investment Authority
Abzena
Adimmune
Adjuvant Capital
Advagene Biopharma
Affinivax
AJ Biologics
AJ Vaccines
Ajinomoto Bio-Pharma Services
Alexandria Venture Investments
Alopexx Vaccine
Altimmune
AmbioPharm
AMRI
Anaxago
Angels High Tech Investments
Anhui Zhifei Longcom Biologic Pharmacy
ARCH Venture Partners
ArrowMark Partners
Astellas Pharma
Atlantic Methanol Production Company
Auro Vaccines
Avid Bioservices
AVIR Green Hills Biotechnology
aws Gründerfonds
Barr Laboratories
Batavia Biosciences
Bavarian Nordic
Baxter BioPharma Solutions
Baylor College of Medicine
BB Biotech
Beijing Center for Disease Control and Prevention
Beijing Institute of Biological Products
Beijing Minhai Biotechnology
Beijing Zhifei Lvzhu Biopharmaceutical
Bharat Biotech
Bharat Serums and Vaccine
Bill & Melinda Gates Foundation
Bilthoven Biologicals
BINEX
Bio Elpida
Bio Farma
BioCell
BioConnections
Biofabri
Biological E
Bio-Manguinhos
BioMARC
Biomay
Biomedical Advanced Research and Development Authority
BioMedPartners
BiondVax Pharmaceuticals
BioReliance
BioTechLogic
BioTechnique
BlueWillow Biologics
Boehringer Ingelheim BioXcellence
Boehringer Ingelheim Venture Fund
Boryung Pharmaceutical
Brammer Bio
Bryllan
Bul Bio-National Center of Infectious and Parasitic Diseases
Burrard Pharmaceuticals
Cadila Healthcare
CanSino Biologics
CARBOGEN AMCIS
CARB-X
Catalent
Center for Genetic Engineering and Biotechnology
Century Pharmaceuticals
CEPI
Cerberus Capital Management
CEVEC Pharmaceuticals
Charles River Laboratories
Chengdu Institute of Biological Products
Chiron Behring Vaccines
Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences
CJ HealthCare
Cobra Biologics
Codagenix
Consort Medical
CRG
CSL
CureVac
Curevo
Cytovance Biologics
Dalton Pharma Services
Danish Government
Danish Innovation Foundation
Dartmouth-Hitchcock Medical Center
Deerfield Management
Department of the Army
Division of AIDS
Duke Human Vaccine Institute
Dynavax Technologies
EDBI
EDCTP
EirGenix
Emergent BioSolutions
Emergent Product Development Gaithersburg
Emergex Vaccines
Ethiopian Government
EuBiologics
Euclidean Capital
Eurofins Amatsigroup
Eurogentec
European Investment Bank
European Union
Eveliqure Biotechnologies
Farallon Capital
Federal State Budgetary Scientific Institution
FF DSF VI
Fidelity Investments
Fiocruz
FluGen
Forbion
Fort Detrick
Fortune Capital
FUJIFILM Diosynth Biotechnologies
FundRx
Future Industry Investment Fund
Gamaleya Research Institute of Epidemiology and Microbiology
GC Cell
GC Pharma
GeneMatrix
GeneOne Life Science
GenIbet Biopharmaceuticals
Georgia Institute of Technology
Gilead
GlaxoSmithKline
Global Health Investment Fund
Goldstone Investment
Gopher Asset Management
Government of Norway
Government of the Republic of Equatorial Guinea
GPO-MBP
GreenPak Biotech
GreenSignal Bio Pharma
GTP Technology
GV
Hadean Ventures
Haffkine Bio-Pharmaceutical
HALIX
Hawaii Biotech
HBM Partners
Health Biotech
HealthCap
Hillhouse Capital
Hong Kong Institute of Biotechnology
HOOKIPA Pharma
Hualan Biological Bacterin
Icahn School of Medicine at Mount Sinai
IDT Biologika
ILiAD Biotechnologies
Il-Yang Pharmaceutical
Immunobiological Technology Institute (BioManguinhos)
Imperial College London
Indian Immunologicals
Infectious Disease Research Institute
Innovate UK
Inovio Pharmaceuticals
Institut Pasteur de Dakar
Institute for Biomedical Science
Institute of Vaccines and Medical Biologicals
Instituto Nacional de Saúde
Intas
Integrity Bio
GC Pharma
GeneMatrix
GeneOne Life Science
GenIbet Biopharmaceuticals
Georgia Institute of Technology
Gilead
GlaxoSmithKline
Global Health Investment Fund
Goldstone Investment
Gopher Asset Management
Government of Norway
Government of the Republic of Equatorial Guinea
GPO-MBP
GreenPak Biotech
GreenSignal Bio Pharma
GTP Technology
GV
Hadean Ventures
Haffkine Bio-Pharmaceutical
HALIX
Hawaii Biotech
HBM Partners
Health Biotech
HealthCap
Hillhouse Capital
Hong Kong Institute of Biotechnology
HOOKIPA Pharma
Hualan Biological Bacterin
Icahn School of Medicine at Mount Sinai
IDT Biologika
ILiAD Biotechnologies
Il-Yang Pharmaceutical
Immunobiological Technology Institute (BioManguinhos)
Imperial College London
Indian Immunologicals
Infectious Disease Research Institute
Innovate UK
Inovio Pharmaceuticals
Institut Pasteur de Dakar
Institute for Biomedical Science
Institute of Vaccines and Medical Biologicals
Instituto Nacional de Saúde
Intas
Integrity Bio
GC Pharma
GeneMatrix
GeneOne Life Science
GenIbet Biopharmaceuticals
Georgia Institute of Technology
Gilead
GlaxoSmithKline
Global Health Investment Fund
Goldstone Investment
Gopher Asset Management
Government of Norway
Government of the Republic of Equatorial Guinea
GPO-MBP
GreenPak Biotech
GreenSignal Bio Pharma
GTP Technology
GV
Hadean Ventures
Haffkine Bio-Pharmaceutical
HALIX
Hawaii Biotech
HBM Partners
Health Biotech
HealthCap
Hillhouse Capital
Hong Kong Institute of Biotechnology
HOOKIPA Pharma
Hualan Biological Bacterin
Icahn School of Medicine at Mount Sinai
IDT Biologika
ILiAD Biotechnologies
Il-Yang Pharmaceutical
Immunobiological Technology Institute (BioManguinhos)
Imperial College London
Indian Immunologicals
Infectious Disease Research Institute
Innovate UK
Inovio Pharmaceuticals
Institut Pasteur de Dakar
Institute for Biomedical Science
Institute of Vaccines and Medical Biologicals
Instituto Nacional de Saúde
Intas
Integrity Bio
PnuVax
Polymun Scientific
Porton Biopharma
Premas Biotech
ProBioGen
Profectus BioSciences
Protein Sciences
PX’Therapeutics
Qiming Venture Partners
Redmile Group
Redmont Capital
Reliance Life Sciences
Research Foundation for Microbial Diseases, Osaka University
Richter-Helm Biologics
Rommelag CMO
RTW Investments
Russian Academy of Sciences
Sabin Vaccine Institute
Samsara BioCapital
Sanaria
Sanofi Pasteur
Scandinavian Biopharma
Scripps Research Institute
SDS Capital Partners
Seedlings Life Science Ventures
SEEK
Seqirus
Sequoia
Sequoia China
Serum Institute of India
Shanghai Bovax Biotechnology
Shantha Biotechnics
Sinovac Biotech
Sirona Capital
SK Bioscience
Sofinnova Partners
State of Wisconsin Investment Board
Sunstone Capital
Sunstone Life Science Ventures
Swissfillon
Syngene
Takeda
Takeda Ventures
Teva Pharmaceuticals
Texas Biomedical Research Institute
The Peter Doherty Institute for Infection and Immunity
The Wistar Institute
Themis Bioscience
Thermo Fisher Scientific
Topspin Partners
Truffle Capital
UK Government
UK Research and Innovation
Univercells
University Health Network
University Medical Center Hamburg-Eppendorf
University of Amsterdam
University of Antwerp
University of California
University of Georgia
University of Maryland
University of Michigan
University of Minnesota
University of Oxford
University of Washington
US Agency for International Development
US Army Contracting Command
US Army Medical Research and Materiel Command
US Centers for Disease Control and Prevention
US Defense Advanced Research Projects Agency
US Defense Threat Reduction Agency
US Department of Agriculture
US Department of Defense
Vaccitech
Valneva
Vaxart
Vaxine
VaxNewMo
Vaxxilon
VBI Vaccines
Ventech
Venture Investors
Vetter Pharma
VGXI
Vibalogics
Vickers Venture Partners
Viking Global Investors
Wacker Biotech
Waisman Biomanufacturing
Wallace Pharmaceuticals
Wellington Partners Life Sciences
Wisconsin Alumni Research Foundation
WuXi Biologics
Wuxi Griffin
Wyeth Pharmaceuticals
Xiamen University
X-Vax Technology

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4314EUR$4,799USD£3,744GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6291EUR$6,999USD£5,461GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16179EUR$17,999USD£14,044GBP